A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function

摘要

Chronic pulmonary complications of haematopoietic SCTs (HSCTs) include interstitial disease and bronchiolitis obliterans (BO). BO almost exclusively occurs in allograft recipients (usually 12 months post HSCT) and is closely associated with chronic GvHD and a poorer outcome post HSCT. Identified risk factors for BO include older age of recipient/donor, pre-transplant lung function abnormalities, female donor for male patients and low levels of IgG. The proportion of HSCT recipients developing lung GvHD varies from 1 to 40% among studies. More accurate data are required for planning controlled trials of treatments such as azithromycin, which is an effective treatment for BO post lung transplantation. We have therefore performed a retrospective study to estimate the current UK prevalence of new lung function impairment following allogeneic HSCT to help plan future prospective studies of aetiological associations or therapies for lung GvHD.